Defunct Company
Total Trials
14
As Lead Sponsor
13
As Collaborator
1
Total Enrollment
683
NCT01007123
Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2009
Completion: Oct 31, 2010
NCT01069783
Study of A3309 in Patients With Dyslipidemia
Start: Feb 28, 2010
Completion: Sep 30, 2010
NCT02963077
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
Phase: Phase 1
Start: Jul 31, 2013
Completion: May 31, 2014
NCT02078856
Double-blind, Randomised Study of A3384 in BAM/BAD
Start: Mar 31, 2014
Completion: Dec 31, 2014
NCT02360852
IBAT Inhibitor A4250 for Cholestatic Pruritus
Role: Collaborator
Start: Jan 31, 2015
Completion: Oct 31, 2016
NCT02630875
A4250, an IBAT Inhibitor in Pediatric Cholestasis
Start: Aug 31, 2015
Completion: Mar 17, 2017
NCT03082937
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
Start: Jan 31, 2017
Completion: Mar 8, 2017
NCT03566238
This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
Phase: Phase 3
Start: May 16, 2018
Completion: Jul 28, 2020
NCT03608319
Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions
Start: Jul 5, 2018
Completion: Aug 18, 2018
NCT04006145
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
Start: Jun 6, 2019
Completion: Jul 15, 2020
NCT04273217
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
Start: Feb 4, 2020
Completion: Jul 8, 2021
NCT04674761
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Start: Mar 19, 2021
Completion: Sep 9, 2022
NCT06799741
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
Start: Jan 7, 2025
Completion: Mar 14, 2026